Safety and Efficacy of Tofacitinib in 97 Alopecia Areata Patients

    Maryam Nasimi, Robabeh Abedini, Narges Ghandi, Amir Teymourpour, Hanie Babaie
    TLDR Tofacitinib is an effective and safe treatment for alopecia areata.
    This retrospective study assessed the safety and efficacy of oral tofacitinib in 97 patients with alopecia areata (AA), alopecia totalis (AT), or alopecia universalis (AU) over at least 6 months. The mean Severity of Alopecia Tool (SALT) score significantly decreased from 77.66% to 29.15% (p < 0.05). Tofacitinib was effective, with 69.1% of patients showing moderate to complete response and 44.3% achieving over 90% change in SALT score. Adverse effects were generally mild, including abnormal lipid profiles (12.3%) and upper respiratory infections (7.2%). No significant correlation was found between treatment response and patient age, sex, or disease duration, but patchy AA patients showed greater improvement. The study concluded that tofacitinib is a safe and effective treatment for AA, AT, and AU, though further research is needed to understand long-term effects and compare different JAK inhibitors.
    Discuss this study in the Community →

    Cited in this study

    8 / 8 results

    Related

    6 / 6 results